Patientcharacteristics
| Number of patients | 355 |
| Mean age in years (SD) | 51.8 (±12.5) |
| Female, n (%) | 256 (71.9) |
| Median disease duration in years (IQR) | 13.1(7.6, 19.3) |
| Race/ethnicity, n (%) | |
| White | 315 (90.5) |
| Non-white | 33 (9.5) |
| MS pattern, n (%) | |
| RMS | 278 (78.3) |
| SPMS | 47 (13.2) |
| PPMS | 30 (8.5) |
| Previous DMT, n (%) | |
| Interferon | 11 (3.1) |
| Glatiramer acetate | 23 (6.6) |
| Fingolimod | 53 (15.1) |
| Dimethyl fumarate | 53 (15.1) |
| Teriflunomide | 20 (5.7) |
| Natalizumab | 66 (18.9) |
| Other Med* | 28 (8.0) |
| Treatment naive | 96 (27.4) |
| Median time in months on OCR (IQR) | 23.6(19.0, 29.7) |
| Time on drug 1 year or less, n (%) | 45 (12.7) |
| Time on drug 1 to 2 years, n (%) | 101 (28.5) |
| Time on drug 2 years or more, n (%) | 209 (58.9) |
| Patients with Infusion reactions—dose 1, n (%) | 125 (35.2) |
| Reaction requiring treatment, n (%) | 89 (25.1) |
| Patients with infusion reactions—subsequent doses,† n (%) | 67 (18.9) |
| Reaction requiring treatment, n (%) | 43 (12.1) |
| Lost to follow-up, n (%) | 23 (6.5) |
| Discontinued, n (%) | 43 (12.1) |
*Other med includes: mycophenolate, intravenous methylprednisolone, daclizumab, cyclophosphamide, azathioprine, and study drugs through clinical trials.
†Among patients who had more than one dose or a 6 month review following first dose (n=337).
DMT, disease-modifying treatment; OCR, ocrelizumab; PPMS, primary progressive multiple sclerosis; RMS, relapsing multiple sclerosis; SPMS, secondary progressive multiple sclerosis.